Gene therapy

Ocugen CEO & CSO to Present at 41st Annual AAPI Convention and Scientific Assembly

Retrieved on: 
Friday, June 30, 2023
Vaccine, Medicine, American Association of Physicians of Indian Origin, Physician, Convention, MBA, Doctor of Philosophy, Development, AAPI, Cell, Entrepreneurship, Gene therapy, Pharmaceutical industry, Bookkeeping

MALVERN, Pa., June 30, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that the Company’s Chairman, CEO and Co-Founder, Shankar Musunuri, PhD, MBA, and Chief Scientific Officer, Head of Research, Development and Medical, Arun Upadhyay, PhD, will present at the American Association of Physicians of Indian Origin (AAPI) Convention and Scientific Assembly, July 6 – 9, 2023 in Philadelphia, PA.

Key Points: 
  • MALVERN, Pa., June 30, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that the Company’s Chairman, CEO and Co-Founder, Shankar Musunuri, PhD, MBA, and Chief Scientific Officer, Head of Research, Development and Medical, Arun Upadhyay, PhD, will present at the American Association of Physicians of Indian Origin (AAPI) Convention and Scientific Assembly, July 6 – 9, 2023 in Philadelphia, PA.
    “The AAPI is an impressive organization that fosters the continued leadership of healthcare professionals of Indian origin through educational and networking opportunities, while also supporting the next generation of leaders and giving back to people in need through its charitable foundation,” said Dr. Musunuri.
  • “We look forward to interacting with top physicians, health professionals, academicians, and scientists from across the country to drive positive change throughout our dynamic healthcare environment.”
    “It’s an honor to share more about Ocugen’s scientific platforms, especially modifier gene therapy, with this important audience,” said Dr. Upadhyay.
  • “Opportunities like this for an open dialogue among industry and practitioners is critical to advancing treatment options and providing access for patients.”
    Details on Dr. Upadhyay’s participation are as follows:
    Product Theater: "Emerging Cell and Gene Therapy Technologies: Novel curative approaches to breaking barriers in disease management"
    Details on Dr. Musunuri’s participation are as follows:

Mass Spectrometry Market worth $6.8 billion | MarketsandMarkets

Retrieved on: 
Monday, June 26, 2023
Symphogen, ASP, Partnership, Cellario, Veolia Water Technologies & Solutions, Center for Cell and Gene Therapy, Table, SLIM, Mass spectrometry, Food safety, Shimadzu, SCIEX, Lipid, Structures for lossless ion manipulations, Intelligence, Unresolved complex mixture, Research, Thermo Fisher Scientific, Noetics, Proteomics, Environmental monitoring, Protein, Data analysis, Acquisition, Echo, Mass, Machine learning, PerkinElmer, Agilent Technologies, Metabolomics, Algorithm, Drug discovery, Quality control, Range, Waters Corporation, Atomic mass, Isotope, Quantitative analysis, Gene therapy, Peptide, Automation, Bruker, Software, Medical imaging, Fine chemical, Computer data storage, Uranium mining, Retail

In summary, the mass spectrometry market offers high sensitivity, structural characterization, versatility, quantitative analysis, selectivity, rapid analysis, and advancements in data analysis.

Key Points: 
  • In summary, the mass spectrometry market offers high sensitivity, structural characterization, versatility, quantitative analysis, selectivity, rapid analysis, and advancements in data analysis.
  • Mass Spectrometry Market – Report Highlights:
    In this report, mass spectrometry are considered, along with tables and accessories, used for healthcare applications pharmaceutical industries.
  • The study consists of the average selling price (ASP) analysis for different products in the mass spectrometry market.
  • These companies have emerged as key market players in recent years due to their products and various strategic investments undertaken in the mass spectrometry market space.

Mass Spectrometry Market worth $6.8 billion | MarketsandMarkets

Retrieved on: 
Monday, June 26, 2023
Symphogen, ASP, Partnership, Cellario, Veolia Water Technologies & Solutions, Center for Cell and Gene Therapy, Table, SLIM, Mass spectrometry, Food safety, Shimadzu, SCIEX, Lipid, Structures for lossless ion manipulations, Intelligence, Unresolved complex mixture, Research, Thermo Fisher Scientific, Noetics, Proteomics, Environmental monitoring, Protein, Data analysis, Acquisition, Echo, Mass, Machine learning, PerkinElmer, Agilent Technologies, Metabolomics, Algorithm, Drug discovery, Quality control, Range, Waters Corporation, Atomic mass, Isotope, Quantitative analysis, Gene therapy, Peptide, Automation, Bruker, Software, Medical imaging, Fine chemical, Computer data storage, Uranium mining, Retail

In summary, the mass spectrometry market offers high sensitivity, structural characterization, versatility, quantitative analysis, selectivity, rapid analysis, and advancements in data analysis.

Key Points: 
  • In summary, the mass spectrometry market offers high sensitivity, structural characterization, versatility, quantitative analysis, selectivity, rapid analysis, and advancements in data analysis.
  • Mass Spectrometry Market – Report Highlights:
    In this report, mass spectrometry are considered, along with tables and accessories, used for healthcare applications pharmaceutical industries.
  • The study consists of the average selling price (ASP) analysis for different products in the mass spectrometry market.
  • These companies have emerged as key market players in recent years due to their products and various strategic investments undertaken in the mass spectrometry market space.

Tessa Therapeutics’ ‘Off-the-Shelf’ CAR-T Therapy Shows Promising Results in Early-Stage Study of Hodgkin Lymphoma

Retrieved on: 
Friday, June 16, 2023
Graft-versus-host disease, Center for Cell and Gene Therapy, GVHD, Epstein–Barr virus, Baylor College of Medicine, ICML, Lymphoma, Baylor University, Cancer, Allotransplantation, Cell, Infrastructure as code, Asilomar International Conference on Climate Intervention Technologies, Cytokine release syndrome, Patient, Risk, HL, Immune system, Therapy, Conference, Gene therapy, Safety, Bone marrow, Pharmaceutical industry, Vaccine

The results were presented by Tessa collaborators at the Baylor College of Medicine in an oral podium presentation at the 17th International Conference on Malignant Lymphoma (ICML) taking place at Lugano, Switzerland.

Key Points: 
  • The results were presented by Tessa collaborators at the Baylor College of Medicine in an oral podium presentation at the 17th International Conference on Malignant Lymphoma (ICML) taking place at Lugano, Switzerland.
  • TT11X, Tessa’s allogeneic “off-the-shelf” cell therapy, is based on Tessa’s proprietary CD30.CAR-modified Epstein-Barr virus-specific T-cell (EBVST) platform.
  • “Importantly, CD30.CAR EBVSTs elicited a clinical response in 14 of 18 patients with R/R Hodgkin lymphoma including seven complete responses.
  • “The data presented at ICML are very promising and further validate our “off-the-shelf” CD30.CAR EBVST allogeneic cell therapy platform in R/R Hodgkin lymphoma,” stated Ivan Horak, M.D., Chief Medical Officer and Chief Scientific Officer of Tessa Therapeutics.

Bayer Strengthens Gene Therapy Portfolio With Lipid Nanoparticle Technology From Acuitas Therapeutics

Retrieved on: 
Tuesday, June 6, 2023
Biotechnology, Pharmaceutical, Genetics, Health, Janus, Vaccine, DNA, Business development, Therapy, COVID-19, Gene editing, Cell, RNA, Messenger, Small RNA, Mobile business development, Patient, Liver, LNP, Gene therapy, Pharmaceutical industry, Acuitas Therapeutics, Bayer

Bayer AG is joining forces with Acuitas Therapeutics, Inc., a biotechnology company specializing in the development of lipid nanoparticle (LNP) delivery systems for molecular therapeutics.

Key Points: 
  • Bayer AG is joining forces with Acuitas Therapeutics, Inc., a biotechnology company specializing in the development of lipid nanoparticle (LNP) delivery systems for molecular therapeutics.
  • Acuitas’ LNP technology will support Bayer’s in vivo gene editing and protein replacement programs with the goal of specifically delivering RNA payloads to the desired target organ, the liver.
  • This delivery technology protects the messenger RNA (mRNA) payload after administration allowing it to be safely and effectively delivered into cells.
  • “Adding Acuitas’ clinically-validated and scalable LNP technology to our genomic medicine toolbox is another important step to advance our leadership in the field of cell and gene therapies.”
    “We are delighted to partner with Bayer in the area of gene therapy.

Oncology Clinical Trials: Solving Complex Challenges with Data-Driven and Innovative Approaches, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Tuesday, June 6, 2023
PPD, Gene, Clinical trial, Clinical research, Thermo Fisher Scientific, Doctor of Philosophy, Collection, Patient, Risk, Master of Science, Cell, Cancer, FACS, Gene therapy, Nursing, Management, MD

TORONTO, June 6, 2023 /PRNewswire-PRWeb/ -- Oncology clinical trials face many challenges today, especially in the context of clinical drug development. These challenges include rapidly changing standards of care and clinical strategies, intense competition for qualified sites and patients, complexity of protocols, enrollment barriers that hinder diversity and inclusion goals, high data volume and collection requirements, and stringent regulatory and payor requirements necessitating long term follow-up.

Key Points: 
  • In this free webinar, learn about the key challenges and complexities with oncology clinical trials, with a focus on cell therapy and early phase trials.
  • The speakers will discuss what leaders, stakeholders & sponsors can do to improve patient access to oncology clinical trials.
  • TORONTO, June 6, 2023 /PRNewswire-PRWeb/ -- Oncology clinical trials face many challenges today, especially in the context of clinical drug development.
  • Join this webinar to discover how data-driven and innovative approaches help tackle complex challenges in oncology clinical trials.

RoslinCT and Lykan Bioscience Announce Integration to Establish Global Advanced Cell and Gene Therapy CDMO Service Offerings

Retrieved on: 
Monday, June 5, 2023
CRISPR, Sheep, University, Center for Cell and Gene Therapy, Gene, IPSC, Advanced Cell Therapeutics, Gene editing, History, Science, Organization, Roslin Institute, CGMP, Gene therapy, Disease, Fine chemical, Cell, Atlantic Ocean

EDINBURGH, U.K. and BOSTON, U.S., June 5, 2023 /PRNewswire/ -- RoslinCT and Lykan Bioscience, two leading Contract Development and Manufacturing Organizations (CDMOs) in the Cell and Gene Therapy industry, announce their integration, creating a unified business that will operate under the RoslinCT brand.

Key Points: 
  • EDINBURGH, U.K. and BOSTON, U.S., June 5, 2023 /PRNewswire/ -- RoslinCT and Lykan Bioscience, two leading Contract Development and Manufacturing Organizations (CDMOs) in the Cell and Gene Therapy industry, announce their integration, creating a unified business that will operate under the RoslinCT brand.
  • The integration, facilitated by GHO Capital, a global investment firm, aims to establish a dominant player in the Advanced Cell and Gene Therapy CDMO market.
  • These services will empower Cell and Gene Therapy developers to advance their products through clinical trials and bring them to market.
  • Our proven experience in Cell and Gene Therapy, coupled with our combined global capabilities, will provide our partners with superior service and support as we continue to advance life-saving therapies worldwide."

RoslinCT and Lykan Bioscience Announce Integration to Establish Global Advanced Cell and Gene Therapy CDMO Service Offerings

Retrieved on: 
Monday, June 5, 2023
CRISPR, Sheep, University, Center for Cell and Gene Therapy, Gene, IPSC, Advanced Cell Therapeutics, Gene editing, History, Science, Organization, Roslin Institute, CGMP, Gene therapy, Disease, Fine chemical, Cell, Atlantic Ocean

EDINBURGH, U.K. and BOSTON, U.S., June 5, 2023 /PRNewswire/ -- RoslinCT and Lykan Bioscience, two leading Contract Development and Manufacturing Organizations (CDMOs) in the Cell and Gene Therapy industry, announce their integration, creating a unified business that will operate under the RoslinCT brand.

Key Points: 
  • EDINBURGH, U.K. and BOSTON, U.S., June 5, 2023 /PRNewswire/ -- RoslinCT and Lykan Bioscience, two leading Contract Development and Manufacturing Organizations (CDMOs) in the Cell and Gene Therapy industry, announce their integration, creating a unified business that will operate under the RoslinCT brand.
  • The integration, facilitated by GHO Capital, a global investment firm, aims to establish a dominant player in the Advanced Cell and Gene Therapy CDMO market.
  • These services will empower Cell and Gene Therapy developers to advance their products through clinical trials and bring them to market.
  • Our proven experience in Cell and Gene Therapy, coupled with our combined global capabilities, will provide our partners with superior service and support as we continue to advance life-saving therapies worldwide."

Poseida Therapeutics to Present at Stifel 2023 Tailoring Genes: Genetic Medicines Day

Retrieved on: 
Tuesday, May 23, 2023
Webcast, Cancer, Rare, Medication, Therapy, Patient, SAN, Gene therapy, Pharmaceutical industry, Broadcasting, Vaccine

SAN DIEGO, May 23, 2023 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, today announced that the Company's President of Gene Therapy, Brent Warner, will participate in a virtual fireside chat at the Stifel 2023 Tailoring Genes: Genetic Medicines Day on Tuesday, May 30, 2023 at 12:00pm PT | 03:00pm ET.

Key Points: 
  • SAN DIEGO, May 23, 2023 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, today announced that the Company's President of Gene Therapy, Brent Warner, will participate in a virtual fireside chat at the Stifel 2023 Tailoring Genes: Genetic Medicines Day on Tuesday, May 30, 2023 at 12:00pm PT | 03:00pm ET.
  • A live webcast of the fireside chat will be available on the Investors & Media Section of Poseida's website, www.poseida.com .
  • A replay of the webcast will be available for approximately 90 days following the presentation.

Mary Kay Inc. & European Society for Dermatological Research Partner to Award Educational Research Grants Advancing Skin Health/Skin Disease

Retrieved on: 
Wednesday, May 17, 2023
Cosmetics, Men, Retail, Health, Consumer, Lifestyle, Oncology, Research, Infectious Diseases, General Health, Genetics, Fitness & Nutrition, Science, Women, Human, Society, Partnership, Skin care, ETH, Human Cell Atlas, Skin, Dermatology, Skin cancer, Cancer, ESDR, Multimedia, Regenerative medicine, Assistant professor, Vivo, Tissue Engineering and Regenerative Medicine International Society, Mary Kay, Gene therapy, ISCB Senior Scientist Award, Biology, European Society for Clinical Investigation, Carcinoma, BCC, Tumor microenvironment, Conference, Pharmaceutical industry

Mary Kay Inc. , a global leader in skin care innovation, in partnership with the European Society for Dermatological Research , recently announced its inaugural Mary Kay Skin Health/Skin Disease Research Grant awardees at a special virtual event prior to the First International Societies for Investigative Dermatology conference in May.

Key Points: 
  • Mary Kay Inc. , a global leader in skin care innovation, in partnership with the European Society for Dermatological Research , recently announced its inaugural Mary Kay Skin Health/Skin Disease Research Grant awardees at a special virtual event prior to the First International Societies for Investigative Dermatology conference in May.
  • View the full release here: https://www.businesswire.com/news/home/20230517005040/en/
    Mary Kay partnered with European Society for Dermatological Research (ESDR) to award inaugural Mary Kay-ESDR Skin Health/Skin Disease Research Grants.
  • Congratulations to our 2022 recipients, Dr. Clarisse Ganier and Dr. Michael Cangkrama, who will each receive $20,000 grants to further their contributions in skin disease research.
  • (Photo: Mary Kay Inc.)
    “Mary Kay is dedicated to advancing skin and nutritional health research globally, and we know this cannot be done alone.